Start Date
June 27, 2019
Primary Completion Date
November 30, 2022
Study Completion Date
November 30, 2022
Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
Fluticasone furoate/umeclidinium/vilanterol
The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
GSK Investigational Site, Charlotte
GSK Investigational Site, Layton
GSK Investigational Site, Waterbury
Lead Sponsor
GlaxoSmithKline
INDUSTRY